PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3898035

Flecainide: a new prototype antiarrhythmic agent.

J M Nappi·J L Anderson
View original source ↗Export metadata ↓

Abstract

Flecainide acetate is the first class IC antiarrhythmic agent marketed in the United States. In vitro, animal and human studies have shown that the drug markedly prolongs conduction and has minimal effect on repolarization. Efficacy trials have shown flecainide to be effective in a wide range of ventricular and selected atrial arrhythmias. The drug is generally well tolerated, although minor adverse effects are common. These generally are related to the central nervous system and respond to a reduction in dosage. Like other antiarrhythmic agents, flecainide may demonstrate proarrhythmic effects. It is excreted in the urine as the parent compound and inactive metabolites. The elimination half-life ranges from 12-27 hours in patients with normal renal function, allowing convenient dosing regimens of 100-200 mg twice daily in most patients. Flecainide has the potential for widespread use.

Explore related subjects

Administration, OralAnimalsAnti-Arrhythmia AgentsArrhythmias, CardiacClinical Trials as TopicDisopyramideDrug InteractionsElectrocardiographyFlecainideHeartHeart Conduction SystemHemodynamicsHumansIn Vitro TechniquesInjections, IntravenousPiperidinesProtein BindingQuinidineTachycardiaClinical TrialJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J M Nappi, J L Anderson. Flecainide: a new prototype antiarrhythmic agent.. https://doi.org/10.1002/j.1875-9114.1985.tb03419.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Cellular evaluation of oral chemotherapy carriers.

Hydrogel nanospheres composed of methacrylic acid and poly(ethylene glycol) were loaded with bleomycin and tested as a potential oral delivery system for chemotherapeutic agents. The gastrointestinal epithelium was modeled through the use of Caco-2 monolayers for studies of permeation enhancement by the carriers as well as bleomycin transport. Bleomycin efficacy following release from the carrier was evaluated with a DLD-1 tumor cell model. The nanospheres release bleomycin in response to a pH increase similar to that seen when passing from the stomach into the upper small intestine. These carriers can also increase the permeability of a model of the epithelial barrier, which would hopefully improve drug transport into the bloodstream. Efficacy studies using a tumor cell model showed retention of activity for bleomycin following loading and release from the nanospheres. The carriers described performed well during in vitro evaluation and can hopefully expand the spectrum of chemotherapeutic agents capable of being administered orally.

Administration, Oral↗
PubMed2005

Autoshaping of chlordiazepoxide drinking in non-deprived rats.

Effects of autoshaping procedures (Paired versus Random) and sipper fluid [chlordiazepoxide (CDP) versus water] on sipper-directed drinking were evaluated in 32 male Long-Evans rats maintained with free access to food and water. For the Paired/CDP group (n = 16), autoshaping procedures consisted of the presentation of the CDP sipper conditioned stimulus (CS) followed by the response-independent presentation of the food unconditioned stimulus (US). The concentration of CDP in the sipper CS (0.05, 0.10, 0.15, 0.20, and 0.25 mg/ml CDP) was increased across sessions. The Paired/Water group (n = 8) received only water in the sipper CS. The Random/CDP group (n = 8) received the CDP sipper CS and food US randomly with respect to one another. The Paired/CDP group drank significantly more of the 0.20 mg/ml and 0.25 mg/ml CDP solutions than the Random/CDP control, and more fluid than the Paired/Water control group when the sipper CS for the Paired/CDP group contained the three highest concentrations of CDP. CS-Only extinction procedures reliably reduced sipper CS-directed drinking in the Paired/CDP and the Paired/Water groups, but not in the Random/CDP group. Data are consistent with the hypothesis that Pavlovian autoshaping procedures induce sipper CS-directed drinking of CDP in rats deprived of neither food nor fluid. Implications for the autoshaping model of drug abuse are discussed.

Administration, Oral↗
PubMed2005

Effect of lead exposure on dopaminergic transmission in the rat brain.

Lead is a neurotoxicant with known behavioral and neurochemical effects. In this study we attempted to relate the behavioral effects of lead to neurotransmission. Oral administration of 1000 ppm of lead acetate to young rats for 30 days caused a reduction in locomotor activity and stereotypic exploratory behavior during a 20 min testing period. This locomotor hypoactivity induced by lead was accompanied by a reduction in stereotypic behavior (sniffing, lickings, biting and grooming). These outcomes suggested that lead might interfere with catecholaminergic and particularly dopaminergic neurotransmission. Therefore, we examined the effect of the lead acetate on the uptake of dopamine in striatal synaptosomal preparations. The collected data showed a clear inhibition of the uptake of 3H-DA with an IC50 of 3.5 x 10(-5)M. This inhibition of the uptake of dopamine suggests that the behavioral effects of lead may be involved in dopaminergic neurotransmission.

Administration, Oral↗